FDA Inspection 1052060 — Bloodworks

Bloodworks — FEI 3071347

The FDA completed an inspection of Bloodworks on May 4, 2018 in Seattle, WA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
May 4, 2018
Fiscal Year
2018
Product Type
Biologics
Project Area
Bioresearch Monitoring
Location
Seattle, WA (United States)

Additional Details

Clinical Investigator (CI)